ATE178074T1 - Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes - Google Patents

Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes

Info

Publication number: ATE178074T1
Authority: AT; Austria
Prior art keywords: proinsulin; type; diabetes; peptide compounds; proinsulin peptide
Prior art date: 1994-07-08

Application number

AT95926642T

Other languages

English (en)

Inventor

William F Hickey

Ann C Griffin

Original Assignee

Dartmouth College

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-08

Filing date

1995-07-07

Publication date

1999-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE178074(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-07-07 Application filed by Dartmouth College filed Critical Dartmouth College

1999-04-15 Application granted granted Critical

1999-04-15 Publication of ATE178074T1 publication Critical patent/ATE178074T1/de

Links

108010076181 Proinsulin Proteins 0.000 title abstract 9
150000001875 compounds Chemical class 0.000 title abstract 7
108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 4
238000001514 detection method Methods 0.000 title 1
230000028993 immune response Effects 0.000 abstract 2
108010075254 C-Peptide Proteins 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Physiology (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Emergency Medicine (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)

AT95926642T 1994-07-08 1995-07-07 Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes ATE178074T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27222094A	1994-07-08	1994-07-08
US47270495A	1995-06-06	1995-06-06

Publications (1)

Publication Number	Publication Date
ATE178074T1 true ATE178074T1 (de)	1999-04-15

Family

ID=26955374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95926642T ATE178074T1 (de)	1994-07-08	1995-07-07	Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes

Country Status (12)

Country	Link
US (1)	US20030220229A1 (de)
EP (1)	EP0788512B1 (de)
JP (1)	JPH10505821A (de)
CN (1)	CN1157621A (de)
AT (1)	ATE178074T1 (de)
AU (1)	AU3094795A (de)
CA (1)	CA2194548A1 (de)
DE (1)	DE69508605T2 (de)
DK (1)	DK0788512T3 (de)
ES (1)	ES2130629T3 (de)
MX (1)	MX9700198A (de)
WO (1)	WO1996001846A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0815136B1 (de)	1995-02-20	2007-06-13	The Walter And Eliza Hall Institute Of Medical Research	Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
SE520392C2 (sv)	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
AUPO269996A0 (en) *	1996-10-01	1996-10-24	Walter And Eliza Hall Institute Of Medical Research, The	A method of prophylaxis and treatment
ES2331342B1 (es) *	2006-05-22	2010-10-13	Consejo Superior Investg.Cientificas	Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
CN103630692B (zh) *	2013-06-02	2015-05-06	马鞍山国声生物技术有限公司	快速检测尿液c肽的胶体金免疫层析试剂盒及其检测方法
CN111879948A (zh) *	2013-10-17	2020-11-03	综合医院公司	鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
GB2523399B (en) *	2014-02-25	2019-03-13	Orban Tihamer	A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
GB2559499A (en) *	2014-02-25	2018-08-08	Orban Tihamer	Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
GB201913408D0 (en) *	2019-09-17	2019-10-30	King S College London	Proinsulin peptides for type 1 diabetes
WO2025035125A1 (en) *	2023-08-10	2025-02-13	The Curators Of The University Of Missouri	Suppression of type 1 diabetes by intrathymic il-4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5210872B2 (de) *	1973-07-14	1977-03-26
US4308181A (en) *	1980-12-08	1981-12-29	American Home Products Corporation	Polypeptide compositions
US4652548A (en) *	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
NL9001083A (nl) *	1990-05-04	1991-12-02	Rijksuniversiteit	Beta-cel antigeen.
JP2649103B2 (ja) *	1990-08-17	1997-09-03	ユニバーシティーオブフロリダ	インシュリン依存性真性糖尿病の早期検出及び処置のための方法及び組成物

1995
- 1995-07-07 MX MX9700198A patent/MX9700198A/es not_active IP Right Cessation
- 1995-07-07 ES ES95926642T patent/ES2130629T3/es not_active Expired - Lifetime
- 1995-07-07 WO PCT/US1995/008596 patent/WO1996001846A1/en not_active Ceased
- 1995-07-07 AU AU30947/95A patent/AU3094795A/en not_active Abandoned
- 1995-07-07 CN CN95194541A patent/CN1157621A/zh active Pending
- 1995-07-07 CA CA002194548A patent/CA2194548A1/en not_active Abandoned
- 1995-07-07 JP JP8504435A patent/JPH10505821A/ja not_active Ceased
- 1995-07-07 AT AT95926642T patent/ATE178074T1/de not_active IP Right Cessation
- 1995-07-07 DE DE69508605T patent/DE69508605T2/de not_active Expired - Fee Related
- 1995-07-07 DK DK95926642T patent/DK0788512T3/da active
- 1995-07-07 EP EP95926642A patent/EP0788512B1/de not_active Revoked
2003
- 2003-01-16 US US10/346,563 patent/US20030220229A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK0788512T3 (da)	1999-10-11
DE69508605T2 (de)	1999-07-22
AU3094795A (en)	1996-02-09
JPH10505821A (ja)	1998-06-09
CN1157621A (zh)	1997-08-20
MX9700198A (es)	1997-04-30
ES2130629T3 (es)	1999-07-01
US20030220229A1 (en)	2003-11-27
EP0788512A1 (de)	1997-08-13
CA2194548A1 (en)	1996-01-25
DE69508605D1 (de)	1999-04-29
WO1996001846A1 (en)	1996-01-25
EP0788512B1 (de)	1999-03-24

Similar Documents

Publication	Publication Date	Title
EP0671920A4 (de)	1996-01-10	Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
ATE32728T1 (de)	1988-03-15	Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel.
WO2004024097A8 (en)	2005-01-13	Compositions and methods for the treatment of immune related diseases
DE3483085D1 (de)	1990-10-04	Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel.
TR199901696T2 (xx)	1999-09-21	Monoklonal veya poliklonal antikorlara ili�kin sabit liyofillenmi� farmakolojik terkipler.
ATE280783T1 (de)	2004-11-15	Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ATE155888T1 (de)	1997-08-15	Zell-test für alzheimersche krankheit
ATE178074T1 (de)	1999-04-15	Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
EP1098642A4 (de)	2004-08-18	Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
DK0845998T3 (da)	2002-02-11	Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69410254D1 (de)	1998-06-18	Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE45153T1 (de)	1989-08-15	Benzisoselenazolthione, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische produkte.
ATE244299T1 (de)	2003-07-15	Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
FR2586428B1 (fr)	1988-11-25	Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
EE05497B1 (et)	2011-12-15	Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DK0568554T3 (da)	1995-12-04	Fremgangsmåde til påvisning af anti-RNA-antistoffer
ATE191568T1 (de)	2000-04-15	Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
TR200504091T2 (tr)	2006-05-22	(7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
DK0764273T3 (da)	1999-06-23	Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
WO1996001846B1 (en)	1996-03-07	Proinsulin peptide compounds for detecting and treating type i diabetes
ATE26841T1 (de)	1987-05-15	Verbindungen zur behandlung von erhoehtem blutdruck.
ES9500002A1 (es)	1995-05-16	Un metodo de tratamiento de la insuficiencia renal progresiva.
DK0972032T3 (da)	2007-04-10	Peptider til behandling af systemisk lupus erythematosus
DE69929683D1 (de)	2006-04-13	Antisense modulierung von lfa-3
ES2128313T3 (es)	1999-05-16	Naftalimidas n-substituidas, su obtencion y empleo.

Legal Events

Date	Code	Title
1999-11-15	UEP	Publication of translation of european patent specification
2006-04-15	REN	Ceased due to non-payment of the annual fee
2008-11-15	RZN	Patent revoked